LEVAMLODIPINE
Parkinsons Disease (PD)
University College, LondonSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Parkinsons Disease (PD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bemdaneprocel BlueRock Therapeutics | Phase 3 | B |
Micardis® University College, London | Phase 3 | B |
GAMMA-GLUTAMYLCYSTEINE Pravat Mandal | Phase 1 | CC |
Same molecule, other indications
LEVAMLODIPINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →